Lurbinectedin is a medication used to treat certain types of cancer. The dosage for lurbinectedin varies depending on the patient's weight and the type of cancer being treated. According to the FDA label [3], the recommended dosage of lurbinectedin is 3.2 mg/m² administered as an intravenous infusion over 60 minutes every 21 days until disease progression or unacceptable toxicity. The dosage should be adjusted for patients with moderate or severe hepatic impairment. The Medscape reference [2] provides the same recommended dosage information as the FDA label. The Drug Patent Watch [1] provides information about the patent for Lurbinectedin but does not provide dosage information. It is important to note that the dosage of lurbinectedin should only be determined by a healthcare professional and should be based on the patient's individual medical condition and response to treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://reference.medscape.com/drug/zepzelca-lurbinectedin-4000075
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf